Mortality Due to Septic Shock Associated With Thrombocytopenia

Septic Shock Clinical Trial

Official title:

Mortality Due to Septic Shock Associated With Thrombocytopenia in the Intensive Care Unit

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03617965
• Other study ID #: UCISEP0718
• Status: Active, not recruiting
• Start date: August 15, 2018
• Est. completion date: December 31, 2019

Study information

• Verified date: September 2019
• Source: Universidad de Guanajuato
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A prospective longitudinal study similar to the one performed by Claushuis and colleagues (2016) will be performed in order to further understand the epidemiology and clinical relationship between platelet levels and mortality secondary to septic shock in a different population. The primary objective is to compare the mortality due to septic shock between patients with thrombocytopenia and patients with normal platelet levels in the ICU of the General Hospital of León, Gto. The secondary objectives are to identify the association between mortality due to septic shock and mild, moderate and severe thrombocytopenia in patients admitted to the ICU at 30, 60 and 90 days.

Research questions

Is there an association between thrombocytopenia and mortality due to septic shock in patients admitted to the critical medicine service? Our hypotheses are that:

1. Mortality from septic shock and thrombocytopenia at 30, 60 and 90 days will be higher in patients with thrombocytopenia than in patients normal platelet counts.

Is there an association between the degree of thrombocytopenia and mortality from septic shock in patients admitted to the critical medicine service? Our hypotheses are that:

1. Mortality from septic shock and thrombocytopenia at 30, 60 and 90 days will be higher in patients with mild thrombocytopenia than in patients without thrombocytopenia.

2. Mortality from septic shock and thrombocytopenia at 30, 60 and 90 days will be higher in patients with moderate thrombocytopenia than in patients without thrombocytopenia.

3. Mortality from septic shock and thrombocytopenia at 30, 60 and 90 days will be higher in patients with severe thrombocytopenia than in patients without thrombocytopenia.

Description:

Background

Sepsis has a high morbidity and mortality, hence is a challenging medical problem throughout the world. Three therapeutic principles must be taken into account to improve organ dysfunction and survival in sepsis: 1) early and adequate antimicrobial therapy; 2) reestablishment of adequate tissue perfusion; and 3) timely identification and control of the septic foci. Moreover, survival in sepsis depends on the timely identification and appropriate treatment. Progressive advances in sepsis management over the past decades have led to reduced mortality indices. Mortality rates have decline progressively from 43% in 1993 to 37% in 2003, to 29% in 2007; furthermore, reaching a low in 2012 of 18.4%. All in all, in order to establish a global outlook and adequate therapeutic algorithms for sepsis, the factors associated with high mortality rates in septic shock must be identified.

Severe sepsis and septic shock are two clinical entities that have a great impact on intra-hospital morbidity and mortality, as well as on the cost of health care systems; accounting for a large proportion among the causes of admission to the intensive care unit (ICU). In the United States in 2013, septicemia was the hospital condition that accounted for the highest cost, reaching a total cost of $23.7 billion dollars (i.e. 6.2% of total hospitalization costs); followed by osteoarthritis (i.e. $16.5 billion dollars, 4.3% of total hospitalization costs), births (i.e. $13.3 billion, 3.5%), complications arising from medical devices, implants or grafts (i.e. $12.4 billion, 3.3%), and acute myocardial infarction (i.e. $12.1 billion, 3.2%).

The prevalence of sepsis at the ICU across multiple centers in Spain ranges between 6 and 30%. Furthermore, more than 50% of patients with sepsis develop severe sepsis and 25% septic shock. Carrillo-Esper and colleagues (2009) report that in Mexican public and private institutions, 27.3% of 40,957 hospitalizations (i.e. 11,183 cases) developed sepsis. This study which included data from ICUs of 24 out of 32 federal entities reports a mortality secondary to sepsis of 30.4%. In Mexico, the hospitalization costs of patients with sepsis is also a cause of concern, with a total estimated cost of $835 million dollars and an average patient cost of $73,000 dollars.

Sepsis definition

The systemic inflammatory response syndrome or SIRS response is the complex pathophysiological reaction to an insult (e.g. infection, trauma, burns). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), defines sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to an infection. Severe sepsis is the sepsis complicated by organ dysfunction, which could progress to septic shock (i.e. sepsis-induced hypotension persisting despite adequate fluid resuscitation). The definitions for sepsis, septic shock, and organ dysfunction have essentially not changed in the past two decades. Despite its global importance, the recognition of sepsis is inadequate. Furthermore, the various manifestations of sepsis make diagnosis difficult, even for experienced physicians. Therefore, a comprehensive definition and clinical guidelines for sepsis management are needed; this would facilitate the clinical identification of sepsis by health professionals, thus improving the diagnostic accuracy and quantification of sepsis.

Thrombocytopenia

Platelets are the smallest blood cells, being only fragments of the megakaryocyte cytoplasm; however, they have a critical role in normal hemostasis and contribute to thrombotic disorders. The normal range of platelets in humans is 150,000-400,000 platelets per microliter of blood. The production of platelets is critically dependent on thrombopoietin, which acts on the differentiation and proliferation of megakaryocyte progenitors and in the maturation of megakaryocytes. Platelets have a short life of up to 10 days. Thrombocytopenia can be classified as: 1) mild, from 100 x 10^9 a 149 x 10^9/L; 2) moderate, from 50 x 10^9 to 99 x 10^9/L; and 3) severe, <50 x 10^9/L. It has been reported that 20% to 50% of patients in the ICU have thrombocytopenia. Aside from hemostatic functions and playing a central role in thrombosis, platelets participate in the immune response. Platelets react to an infectious agent by altering tissue integrity; contributing to the inflammatory cascade, as well as in the elimination process of pathogens and tissue repair. Platelets are activated in patients with SIRS and sepsis. Activation is followed by platelet isolation within the microcirculation and consequently giving rise to a thrombocytopenia. Platelets regulate inflammation and sepsis through multiple mechanisms. Among these mechanisms is innate immunity, where platelets express a receptor for lipopolysaccharide (LPS) Toll-like receptor-4, which contributes to thrombocytopenia through recruitment of neutrophils to the pulmonary system in a systemic response to LPS. Platelets also interact with other leukocytes, including monocytes. The interaction of activated platelets with monocytes induces the nuclear translocation of nuclear factor-kB (NF-kB) and expression of NF-kB dependent inflammatory genes. In addition to direct interactions with leukocytes, platelets contribute to inflammation and immune activation by releasing cytokines and cellular mediators stored in dense and alpha granules. The gold standard for the evaluation of thrombopoiesis is through bone marrow aspiration; however, since bone marrow aspiration is an invasive procedure, it is not frequently performed in clinical conditions such as sepsis.

The association between level of thrombocytopenia (i.e. mild, moderate, and severe) and mortality has been previously studied in sepsis. Claushuis and colleagues (2016), reported the mortality rates of 1,483 consecutive patients admitted to the intensive care unit with sepsis and degrees of thrombocytopenia (i.e. mild, moderate and severe, depending on platelet counts, very low <50 × 10^9/L, intermediate-low 50 × 10^9 to 99 × 10^9/L, low 100 × 10^9 to 149 × 10^9/L) against patients with normal platelet count (i.e. 150 × 10^9 to 399 × 10^9/L). The mortality reported at 30 days was 25.1%, 37.2%, and 54.1% for patients with mild, moderate and severe thrombocytopenia respectively. More studies are needed to confirm the relationship between the platelet levels and septic shock. We decided to conduct a prospective longitudinal study similar to the one performed by Claushuis and colleagues (2016) in our hospital in order to further understand the epidemiology and clinical relationship between platelet levels and mortality secondary to septic shock in a different population.

Complications: septic shock and multiple organ dysfunction

Sepsis can progress to septic shock, multiple organ failure and death if not recognized early. More than 50% of patients with sepsis develop severe sepsis and 25% septic shock; these figures represent 15% of all admissions to the ICU. Septic shock is defined as a septic process associated with circulatory, cellular and metabolic abnormalities; therefore, there is a higher risk of mortality compared to the unique presence of sepsis. Clinically, it includes patients who meet sepsis criteria and who, despite adequate fluid resuscitation, require vasopressors to maintain a mean arterial blood pressure (MAP) above 65mmHg and serum lactate concentration levels above 2 mmol/L. The factors that contribute to septic shock are 1) vasodilation; 2) endothelial dysfunction (i.e. increased permeability due to loss of vascular smooth muscle reactivity secondary to cellular and humoral mediators); 3) hypovolemia; and 4) bilateral ventricular dysfunction.

Multiple organ dysfunction (MOD) refers to progressive organic dysfunction in a severely ill patient; where homeostasis cannot be maintained without intervention. Because of its severity, the organic dysfunction is at one end of the spectrum of severity of the disease. Both infectious conditions (e.g. sepsis, septic shock), and non-infectious conditions (e.g. SIRS for pancreatitis) can present in MOD. MOD can manifest with affection to different systems such as: cardiovascular; pulmonary; hepatic; renal; gastrointestinal; and hematologic, among others. Multiple organ dysfunction can be defined as an increase of two or more points in the Sequential (Sepsis-Related) Organ Function Assessment score (SOFA). It is important to note that the SOFA score is a mark of organic dysfunction; consequently, it does not determine the individual treatment strategies, nor does it predict mortality according to demographic data (e.g. age) or the underlying conditions (e.g. stem cell transplant recipient, postoperative patient). However, the SOFA score helps identify those patients who potentially have a high risk of dying from an infection.

Singer and colleagues (2016) proposed the quickSOFA (qSOFA) scale in order to facilitate the identification of patients at risk of dying from sepsis. The qSOFA scale is a modified version of the SOFA scale, where a score greater than two points is associated with sepsis; consequently, having a poor prognosis. The qSOFA score can be easily calculated as it only has three components. Each component is assigned a point: 1) respiratory rate ≥22 ventilations per minute; 2) alteration of the mental state; and 3) systolic blood pressure ≤100mmHg). Hypoperfusion duration is directly associated with MOD, accounting for a mortality of 70%. According to SOFA score predictions, patients who meet these criteria for septic shock have a higher mortality than patients who do not meet the criteria (i.e. ≥40% versus ≥10%). Raith and colleagues (2017) report that in 182 ICUs in Australia and New Zeland, between 2000 and 2015, 184,875 patients were admitted with a primary admission diagnosis associated with an infectious process. The objective of the aforementioned study was to validate and evaluate the discriminatory capabilities of a two or more points increase in the SOFA score, a two or more increase in SIRS criteria, or a two or more points increase in the qSOFA score among critically ill patients with an infection. The retrospective study reported a greater capacity to predict the intra-hospital mortality of the SOFA scale over the SIRS criteria and qSOFA criteria.

Number of required patients and power calculation

The different sample sizes were calculated to detect statistically significant differences taking as parameters an α = 0.05 and with a statistical power of 0.8 (i.e. 1-β). The work carried out by Claushuis and colleagues (2016) was used to determine the minimum sample size needed to detect statistically significant changes using the categorical variables of mild, moderate and severe thrombocytopenia as previously defined in this protocol at 30, 60 and 90 days of stay in the ICU. The sample size calculator based on proportions of two samples considering the equality of the two extremes (i.e. tails of a Gaussian distribution), was used, available on the web page http://powerandsamplesize.com/. Table 8 summarizes the parameters used to perform these calculations. The parameters are the following: nA, number of patients with normal platelet concentration (i.e. higher than 150,000/μL and lower than 399,000/μL); nB, number of patients with thrombocytopenia; pA, mortality, in percentage, of patients with normal platelet concentration; pB, mortality, in percentage, of patients with thrombocytopenia; k (nA/nB), sampling proportion; N, sample size needed. Taking into account the results, we consider that a sample of more than 30 patients with severe thrombocytopenia is sufficient, while a sample of 105 patients with moderate thrombocytopenia is sufficient. A similar number of patients without thrombocytopenia is needed to make the comparative analysis of mortality.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 350
• Est. completion date: December 31, 2019
• Est. primary completion date: November 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients diagnosed with sepsis (white blood cells >14,000µL) and thrombocytopenia (<150,000/µL).

• Patients who receive care in the ICU of the General Hospital of León, Gto.

• Patients with a complete file with 90-day evolution notes.

Exclusion Criteria:

• Patients diagnosed with cardiogenic, hypovolemic, anaphylactic and neurogenic shock

• Patients older than 80 years or younger than 18 years of age

• Patients referred from another ICU

• Patients with a diagnosis of neoplasia (i.e. hematologic and/or solid tumor)

• Pregnant women

• Patients with liver cirrhosis

• Patients with splenectomy

• Patients with thrombocytosis (i.e.> 400,000/µL) upon admission to ICU

• Patients with previous use of drugs that could produce thrombocytopenia ( e.g. calcium carbonate, acetylsalicylic acid, clopidogrel, dipyridamole, tamoxifen, cisplatin, bexarotene, doxorubicin, and lovastatin.

Elimination Criteria:

• Patients who do not have a follow-up at 30, 60 and 90 days.

Related Conditions & MeSH terms

• Sepsis Bacterial
• Septic Shock
• Shock
• Shock, Septic
• Thrombocytopenia

Intervention

Diagnostic Test:
• Platelet count
All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.

Locations

Country	Name	City	State
Mexico	Hospital General de León	León	Guanajuato

Sponsors (2)

Lead Sponsor	Collaborator
Universidad de Guanajuato	University Medical Center Groningen

Country where clinical trial is conducted

Mexico, 

References & Publications (67)

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10. — View Citation

Armstrong BA, Betzold RD, May AK. Sepsis and Septic Shock Strategies. Surg Clin North Am. 2017 Dec;97(6):1339-1379. doi: 10.1016/j.suc.2017.07.003. Epub 2017 Oct 5. Review. — View Citation

Asaduzzaman M, Lavasani S, Rahman M, Zhang S, Braun OO, Jeppsson B, Thorlacius H. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med. 2009 Apr;37(4):1389-96. doi: 10.1097/CCM.0b013e31819ceb71. — View Citation

Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence. 2014 Jan 1;5(1):20-6. doi: 10.4161/viru.27135. Epub 2013 Nov 13. Review. — View Citation

Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, Diaz-Martin A, Luzzati R, Rosin C, Lagunes L, Trecarichi EM, Sanguinetti M, Posteraro B, Garnacho-Montero J, Sartor A, Rello J, Rocca GD, Antonelli M, Tumbarello M. A multicenter study of — View Citation

Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009 Jul;23(4):177-89. doi: 10.1016/j.blre.2009.04.001. Epub 2009 May 17. Review. — View Citation

Boehme AK, Ranawat P, Luna J, Kamel H, Elkind MS. Risk of Acute Stroke After Hospitalization for Sepsis: A Case-Crossover Study. Stroke. 2017 Mar;48(3):574-580. doi: 10.1161/STROKEAHA.116.016162. Epub 2017 Feb 14. — View Citation

Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26 Suppl 1:S64-74. Review. — View Citation

Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD. [Epidemiological study of sepsis in Mexican intensive care units]. Cir Cir. 2009 Jul-Aug;77(4):301-8; 279-85. English, Spanish. — View Citation

Casserly B, Phillips GS, Schorr C, Dellinger RP, Townsend SR, Osborn TM, Reinhart K, Selvakumar N, Levy MM. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med. 2015 Mar;43(3):567 — View Citation

Churpek MM, Snyder A, Han X, Sokol S, Pettit N, Howell MD, Edelson DP. Quick Sepsis-related Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and Early Warning Scores for Detecting Clinical Deterioration in Infected Patients outside the I — View Citation

Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen-Vercoe E, Devinney R, Doig CJ, Green FH, Kubes P. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in s — View Citation

Claushuis TA, van Vught LA, Scicluna BP, Wiewel MA, Klein Klouwenberg PM, Hoogendijk AJ, Ong DS, Cremer OL, Horn J, Franitza M, Toliat MR, Nürnberg P, Zwinderman AH, Bonten MJ, Schultz MJ, van der Poll T; Molecular Diagnosis and Risk Stratification of Sep — View Citation

Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L, Cupa M, Cohen Y. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med. 2006 Jan;34(1):102-7. — View Citation

Cloutier N, Paré A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S, Boilard E. Platelets can enhance vascular permeability. Blood. 2012 Aug 9;120(6):1334-43. doi: 10.1182/blood-2012-02-413047. Epub 2012 Apr 27. — View Citation

Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest. 2006 Jun;129(6):1432-40. — View Citation

de Oliveira FS, Freitas FG, Ferreira EM, de Castro I, Bafi AT, de Azevedo LC, Machado FR. Positive fluid balance as a prognostic factor for mortality and acute kidney injury in severe sepsis and septic shock. J Crit Care. 2015 Feb;30(1):97-101. doi: 10.10 — View Citation

De Silva E, Kim H. Drug-induced thrombocytopenia: Focus on platelet apoptosis. Chem Biol Interact. 2018 Mar 25;284:1-11. doi: 10.1016/j.cbi.2018.01.015. Epub 2018 Feb 2. Review. — View Citation

Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. Br J Haematol. 2013 Jun;161(6):778-93. doi: 10.1111/bjh.12328. Epub 2013 Apr 18. Review. — View Citation

Dewitte A, Lepreux S, Villeneuve J, Rigothier C, Combe C, Ouattara A, Ripoche J. Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critically [corrected] ill patients? Ann Intensive Care. 2017 Dec 1;7(1):115. doi: 10.1186/s13613-01 — View Citation

Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest. 2006 Apr;129(4):968-78. — View Citation

Esposito S, De Simone G, Boccia G, De Caro F, Pagliano P. Sepsis and septic shock: New definitions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist. 2017 Sep;10:204-212. doi: 10.1016/j.jgar.2017.06.013. Epub 2017 Jul 22. Review. — View Citation

Fujishima S. Organ dysfunction as a new standard for defining sepsis. Inflamm Regen. 2016 Nov 15;36:24. doi: 10.1186/s41232-016-0029-y. eCollection 2016. Review. — View Citation

George JN. Platelets. Lancet. 2000 Apr 29;355(9214):1531-9. Review. — View Citation

Girard TD, Opal SM, Ely EW. Insights into severe sepsis in older patients: from epidemiology to evidence-based management. Clin Infect Dis. 2005 Mar 1;40(5):719-27. Epub 2005 Jan 28. — View Citation

Greco E, Lupia E, Bosco O, Vizio B, Montrucchio G. Platelets and Multi-Organ Failure in Sepsis. Int J Mol Sci. 2017 Oct 20;18(10). pii: E2200. doi: 10.3390/ijms18102200. Review. — View Citation

Gupta S, Sakhuja A, Kumar G, McGrath E, Nanchal RS, Kashani KB. Culture-Negative Severe Sepsis: Nationwide Trends and Outcomes. Chest. 2016 Dec;150(6):1251-1259. doi: 10.1016/j.chest.2016.08.1460. Epub 2016 Sep 9. — View Citation

Haas SA, Lange T, Saugel B, Petzoldt M, Fuhrmann V, Metschke M, Kluge S. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients. Intensive Care Med. 2016 Feb;42(2):202-10. doi: 10.1007/s00134-015-4127-0. Epub 2015 No — View Citation

Hara T, Shimizu K, Ogawa F, Yanaba K, Iwata Y, Muroi E, Takenaka M, Komura K, Hasegawa M, Fujimoto M, Sato S. Platelets control leukocyte recruitment in a murine model of cutaneous arthus reaction. Am J Pathol. 2010 Jan;176(1):259-69. doi: 10.2353/ajpath. — View Citation

Herrán-Monge R, Muriel-Bombín A, García-García MM, Merino-García PA, Martínez-Barrios M, Andaluz D, Ballesteros JC, Domínguez-Berrot AM, Moradillo-Gonzalez S, Macías S, Álvarez-Martínez B, Fernández-Calavia MJ, Tarancón C, Villar J, Blanco J. Epidemiology — View Citation

Hollenberg SM. Inotrope and vasopressor therapy of septic shock. Crit Care Nurs Clin North Am. 2011 Mar;23(1):127-48. doi: 10.1016/j.ccell.2010.12.008. — View Citation

Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. QJM. 1996 Jul;89(7):515-22. — View Citation

Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, van Vught LA, Schultz MJ, van der Poll T, Bonten MJ, Cremer OL; MARS Consortium *. Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis — View Citation

Knaus WA, Sun X, Nystrom O, Wagner DP. Evaluation of definitions for sepsis. Chest. 1992 Jun;101(6):1656-62. — View Citation

Koyama K, Katayama S, Muronoi T, Tonai K, Goto Y, Koinuma T, Shima J, Nunomiya S. Time course of immature platelet count and its relation to thrombocytopenia and mortality in patients with sepsis. PLoS One. 2018 Jan 30;13(1):e0192064. doi: 10.1371/journal — View Citation

Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980 Mar;68(3):344-55. Review. — View Citation

Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995 Oct;23(10):1638-52. Review. — View Citation

Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006 Jan;34(1):15-21. — View Citation

Minasyan H. Sepsis and septic shock: Pathogenesis and treatment perspectives. J Crit Care. 2017 Aug;40:229-242. doi: 10.1016/j.jcrc.2017.04.015. Epub 2017 Apr 18. Review. — View Citation

Nduka OO, Parrillo JE. The pathophysiology of septic shock. Crit Care Nurs Clin North Am. 2011 Mar;23(1):41-66. doi: 10.1016/j.ccell.2010.12.003. Review. — View Citation

Netea MG, van der Meer JW. Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med. 2011 Jan 6;364(1):60-70. doi: 10.1056/NEJMra1001976. Review. — View Citation

O'Brien JM Jr, Lu B, Ali NA, Martin GS, Aberegg SK, Marsh CB, Lemeshow S, Douglas IS. Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med. 2007 Feb;35(2): — View Citation

Peres Bota D, Lopes Ferreira F, Mélot C, Vincent JL. Body temperature alterations in the critically ill. Intensive Care Med. 2004 May;30(5):811-6. Epub 2004 Feb 4. — View Citation

Poutsiaka DD, Davidson LE, Kahn KL, Bates DW, Snydman DR, Hibberd PL. Risk factors for death after sepsis in patients immunosuppressed before the onset of sepsis. Scand J Infect Dis. 2009;41(6-7):469-79. doi: 10.1080/00365540902962756. — View Citation

Prescott HC, Dickson RP, Rogers MA, Langa KM, Iwashyna TJ. Hospitalization Type and Subsequent Severe Sepsis. Am J Respir Crit Care Med. 2015 Sep 1;192(5):581-8. doi: 10.1164/rccm.201503-0483OC. — View Citation

Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, Pilcher DV; Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE). Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Sc — View Citation

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima — View Citation

Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):13 — View Citation

Ruiz-Alvarez MJ, García-Valdecasas S, De Pablo R, Sanchez García M, Coca C, Groeneveld TW, Roos A, Daha MR, Arribas I. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med. 2 — View Citation

Russell JA, Rush B, Boyd J. Pathophysiology of Septic Shock. Crit Care Clin. 2018 Jan;34(1):43-61. doi: 10.1016/j.ccc.2017.08.005. Review. — View Citation

Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, Runyon MS, Self WH, Courtney DM, Nowak RM, Gaieski DF, Ebmeyer S, Johannes S, Wiemer JC, Schwabe A, Shapiro NI. Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From — View Citation

Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, Deutschman CS, Escobar GJ, Angus DC. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsi — View Citation

Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consens — View Citation

Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med. 2006 Oct;34(10):2588-95. — View Citation

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International C — View Citation

Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis. 2007 Mar;7(3):210-7. Review. — View Citation

Tang Y, Choi J, Kim D, Tudtud-Hans L, Li J, Michel A, Baek H, Hurlow A, Wang C, Nguyen HB. Clinical predictors of adverse outcome in severe sepsis patients with lactate 2-4 mM admitted to the hospital. QJM. 2015 Apr;108(4):279-87. doi: 10.1093/qjmed/hcu18 — View Citation

Theerawit P, Na Petvicharn C, Tangsujaritvijit V, Sutherasan Y. The Correlation Between Arterial Lactate and Venous Lactate in Patients With Sepsis and Septic Shock. J Intensive Care Med. 2018 Feb;33(2):116-120. doi: 10.1177/0885066616663169. Epub 2016 Au — View Citation

Thiery-Antier N, Binquet C, Vinault S, Meziani F, Boisramé-Helms J, Quenot JP; EPIdemiology of Septic Shock Group. Is Thrombocytopenia an Early Prognostic Marker in Septic Shock? Crit Care Med. 2016 Apr;44(4):764-72. doi: 10.1097/CCM.0000000000001520. — View Citation

Tolsma V, Schwebel C, Azoulay E, Darmon M, Souweine B, Vesin A, Goldgran-Toledano D, Lugosi M, Jamali S, Cheval C, Adrie C, Kallel H, Descorps-Declere A, Garrouste-Orgeas M, Bouadma L, Timsit JF. Sepsis severe or septic shock: outcome according to immune — View Citation

Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013: Statistical Brief #204. 2016 May. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Rese — View Citation

van Vught LA, Wiewel MA, Klein Klouwenberg PM, Hoogendijk AJ, Scicluna BP, Ong DS, Cremer OL, Horn J, Bonten MM, Schultz MJ, van der Poll T; Molecular Diagnosis and Risk Stratification of Sepsis Consortium. Admission Hyperglycemia in Critically Ill Sepsis — View Citation

Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) St — View Citation

Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 2011 Nov 23;306(20):2248-54. doi: 10.1001/jama.2011.1615. Epub 2011 N — View Citation

Wang B, Chen G, Cao Y, Xue J, Li J, Wu Y. Correlation of lactate/albumin ratio level to organ failure and mortality in severe sepsis and septic shock. J Crit Care. 2015 Apr;30(2):271-5. doi: 10.1016/j.jcrc.2014.10.030. Epub 2014 Nov 11. — View Citation

Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, Crowther M, Warkentin TE, Dodek P, Cade J, Lesur O, Lim W, Fowler R, Lamontagne F, Langevin S, Freitag A, Muscedere J, Friedrich JO, Geerts W, Burry L, Alhashemi J, Cook D; PRO — View Citation

Zahar JR, Timsit JF, Garrouste-Orgeas M, Français A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C. Outcomes in severe sepsis and patients with septic shock: pathogen species and inf — View Citation

* Note: There are 67 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival and mortality rate	Multivariate-adjusted Cox proportional hazards regression models will be used to study the relationship between the diagnostic groups upon admission to the ICU and the mortality rate. Cox regression models adjusted to control the influence of sociodemographic variables will be used. Kaplan-Meier graphs will be used to show differences in the risk of progression to sepsis, septic shock, and death at 30 days.	30 days after ICU admission
Secondary	Survival and mortality rate	Multivariate-adjusted Cox proportional hazards regression models will be used to study the relationship between the diagnostic groups upon admission to the ICU and the mortality rate. Cox regression models adjusted to control the influence of sociodemographic variables will be used. Kaplan-Meier graphs will be used to show differences in the risk of progression to sepsis, septic shock, and death at 60 days.	60 days after ICU admission
Secondary	Survival and mortality rate	Multivariate-adjusted Cox proportional hazards regression models will be used to study the relationship between the diagnostic groups upon admission to the ICU and the mortality rate. Cox regression models adjusted to control the influence of sociodemographic variables will be used. Kaplan-Meier graphs will be used to show differences in the risk of progression to sepsis, septic shock, and death at 90 days.	90 days after ICU admission
Secondary	Association between platelet levels and diagnosis	Will be evaluated using a principal component analysis.	30 days after ICU admission
Secondary	Platelet serum levels will be compared with the different clinical outcomes	The potentially associated variables will be added through the analysis of covariance (ANCOVA) or linear regression adjusted for age, sex, and diagnosis depending on the most appropriate model to assess the prognostic factors to develop sepsis.	30 days after ICU admission